Minerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Minerva Neurosciences (NASDAQ:NERV) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12), Zacks reports.

Minerva Neurosciences Stock Down 2.7 %

NERV traded down $0.08 during trading on Wednesday, hitting $2.86. The company had a trading volume of 11,613 shares, compared to its average volume of 69,688. The company has a market capitalization of $20.00 million, a PE ratio of -0.64 and a beta of 0.15. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The firm’s 50-day moving average price is $3.15 and its 200 day moving average price is $3.92.

Wall Street Analyst Weigh In

NERV has been the topic of several research reports. StockNews.com initiated coverage on shares of Minerva Neurosciences in a research report on Tuesday. They issued a “sell” rating on the stock. HC Wainwright cut their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.